Filing Flows › Zevra Therapeutics (ZVRA) › How it makes money
How Zevra Therapeutics (ZVRA) makes money
Zevra Therapeutics (ZVRA) made $37.8M of revenue in the third quarter 2026 (Q3 2026), +45% from a year earlier. Of every dollar of revenue, 31¢ was left as operating profit, 51¢ was left as net earnings.
Drawing the Sankey…
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $37.8M | 100.0% |
| Operating profit | $11.6M | 30.7% |
| Income tax | $510K | 1.4% |
| Net earnings | $19.2M | 50.9% |
| Operating cash flow | $10.0M | 26.6% |
| Free cash flow | $9.8M | 26.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $37.8M | +45% |
| Q2 2026 | $39.7M | +53% |
| Q1 2026 | $36.2M | +78% |
| Q4 2025 | $34.1M | +183% |
| Q3 2025 | $26.1M | +605% |
| Q2 2025 | $25.9M | +482% |
| Q1 2025 | $20.4M | +496% |
From Zevra Therapeutics' 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does Zevra Therapeutics make money?
Zevra Therapeutics (ZVRA) made $37.8M of revenue in the third quarter 2026 (Q3 2026), +45% from a year earlier. Of every dollar of revenue, 31¢ was left as operating profit, 51¢ was left as net earnings.
What is Zevra Therapeutics' profit margin?
Net earnings were $19.2M, 50.9% of revenue, in the third quarter 2026; the operating margin was 30.7%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.